Global Retinal Drugs and Biologics Market Research Report 2021

1 Retinal Drugs and Biologics Market Overview

• 1.1 Product Overview and Scope of Retinal Drugs and Biologics
• 1.2 Retinal Drugs and Biologics Segment by Type
  • 1.2.1 Global Retinal Drugs and Biologics Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Age Related Macular Degeneration
  • 1.2.3 Diabetic Retinopathy
  • 1.2.4 Ocular Inflammatory Disease (Uveitis)
  • 1.2.5 Macular Hole
• 1.3 Retinal Drugs and Biologics Segment by Application
  • 1.3.1 Retinal Drugs and Biologics Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Others
• 1.4 Global Retinal Drugs and Biologics Market Size Estimates and Forecasts
  • 1.4.1 Global Retinal Drugs and Biologics Revenue 2016-2027
  • 1.4.2 Global Retinal Drugs and Biologics Sales 2016-2027
  • 1.4.3 Retinal Drugs and Biologics Market Size by Region: 2016 Versus 2021 Versus 2027

2 Retinal Drugs and Biologics Market Competition by Manufacturers

• 2.1 Global Retinal Drugs and Biologics Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Retinal Drugs and Biologics Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Retinal Drugs and Biologics Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Retinal Drugs and Biologics Manufacturing Sites, Area Served, Product Type
• 2.5 Retinal Drugs and Biologics Market Competitive Situation and Trends
  • 2.5.1 Retinal Drugs and Biologics Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Retinal Drugs and Biologics Players Market Share by Revenue
  • 2.5.3 Global Retinal Drugs and Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Retinal Drugs and Biologics Retrospective Market Scenario by Region

• 3.1 Global Retinal Drugs and Biologics Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Retinal Drugs and Biologics Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Retinal Drugs and Biologics Market Facts & Figures by Country
  • 3.3.1 North America Retinal Drugs and Biologics Sales by Country
  • 3.3.2 North America Retinal Drugs and Biologics Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Retinal Drugs and Biologics Market Facts & Figures by Country
  • 3.4.1 Europe Retinal Drugs and Biologics Sales by Country
  • 3.4.2 Europe Retinal Drugs and Biologics Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Retinal Drugs and Biologics Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Retinal Drugs and Biologics Sales by Region
  • 3.5.2 Asia Pacific Retinal Drugs and Biologics Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Retinal Drugs and Biologics Market Facts & Figures by Country
  • 3.6.1 Latin America Retinal Drugs and Biologics Sales by Country
  • 3.6.2 Latin America Retinal Drugs and Biologics Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Retinal Drugs and Biologics Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Retinal Drugs and Biologics Sales by Country
  • 3.7.2 Middle East and Africa Retinal Drugs and Biologics Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Retinal Drugs and Biologics Historic Market Analysis by Type

• 4.1 Global Retinal Drugs and Biologics Sales Market Share by Type (2016-2021)
• 4.2 Global Retinal Drugs and Biologics Revenue Market Share by Type (2016-2021)
• 4.3 Global Retinal Drugs and Biologics Price by Type (2016-2021)

5 Global Retinal Drugs and Biologics Historic Market Analysis by Application

• 5.1 Global Retinal Drugs and Biologics Sales Market Share by Application (2016-2021)
• 5.2 Global Retinal Drugs and Biologics Revenue Market Share by Application (2016-2021)
• 5.3 Global Retinal Drugs and Biologics Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 ALLERGAN
  • 6.1.1 ALLERGAN Corporation Information
  • 6.1.2 ALLERGAN Description and Business Overview
  • 6.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 ALLERGAN Product Portfolio
  • 6.1.5 ALLERGAN Recent Developments/Updates
• 6.2 AbbVie
  • 6.2.1 AbbVie Corporation Information
  • 6.2.2 AbbVie Description and Business Overview
  • 6.2.3 AbbVie Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 AbbVie Product Portfolio
  • 6.2.5 AbbVie Recent Developments/Updates
• 6.3 Alimera Sciences
  • 6.3.1 Alimera Sciences Corporation Information
  • 6.3.2 Alimera Sciences Description and Business Overview
  • 6.3.3 Alimera Sciences Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Alimera Sciences Product Portfolio
  • 6.3.5 Alimera Sciences Recent Developments/Updates
• 6.4 Janssen Biotech
  • 6.4.1 Janssen Biotech Corporation Information
  • 6.4.2 Janssen Biotech Description and Business Overview
  • 6.4.3 Janssen Biotech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Janssen Biotech Product Portfolio
  • 6.4.5 Janssen Biotech Recent Developments/Updates
• 6.5 Swedish Orphan Biovitrum
  • 6.5.1 Swedish Orphan Biovitrum Corporation Information
  • 6.5.2 Swedish Orphan Biovitrum Description and Business Overview
  • 6.5.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Swedish Orphan Biovitrum Product Portfolio
  • 6.5.5 Swedish Orphan Biovitrum Recent Developments/Updates
• 6.6 Roche
  • 6.6.1 Roche Corporation Information
  • 6.6.2 Roche Description and Business Overview
  • 6.6.3 Roche Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Roche Product Portfolio
  • 6.6.5 Roche Recent Developments/Updates
• 6.7 Bristol-Myers Squibb
  • 6.6.1 Bristol-Myers Squibb Corporation Information
  • 6.6.2 Bristol-Myers Squibb Description and Business Overview
  • 6.6.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Bristol-Myers Squibb Product Portfolio
  • 6.7.5 Bristol-Myers Squibb Recent Developments/Updates
• 6.8 Genzyme
  • 6.8.1 Genzyme Corporation Information
  • 6.8.2 Genzyme Description and Business Overview
  • 6.8.3 Genzyme Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Genzyme Product Portfolio
  • 6.8.5 Genzyme Recent Developments/Updates
• 6.9 Genentech
  • 6.9.1 Genentech Corporation Information
  • 6.9.2 Genentech Description and Business Overview
  • 6.9.3 Genentech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Genentech Product Portfolio
  • 6.9.5 Genentech Recent Developments/Updates
• 6.10 OCULAR THERAPEUTIX
  • 6.10.1 OCULAR THERAPEUTIX Corporation Information
  • 6.10.2 OCULAR THERAPEUTIX Description and Business Overview
  • 6.10.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 OCULAR THERAPEUTIX Product Portfolio
  • 6.10.5 OCULAR THERAPEUTIX Recent Developments/Updates
• 6.11 Bausch & Lomb
  • 6.11.1 Bausch & Lomb Corporation Information
  • 6.11.2 Bausch & Lomb Retinal Drugs and Biologics Description and Business Overview
  • 6.11.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Bausch & Lomb Product Portfolio
  • 6.11.5 Bausch & Lomb Recent Developments/Updates
• 6.12 UCBCares
  • 6.12.1 UCBCares Corporation Information
  • 6.12.2 UCBCares Retinal Drugs and Biologics Description and Business Overview
  • 6.12.3 UCBCares Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 UCBCares Product Portfolio
  • 6.12.5 UCBCares Recent Developments/Updates

7 Retinal Drugs and Biologics Manufacturing Cost Analysis

• 7.1 Retinal Drugs and Biologics Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Retinal Drugs and Biologics
• 7.4 Retinal Drugs and Biologics Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Retinal Drugs and Biologics Distributors List
• 8.3 Retinal Drugs and Biologics Customers

9 Retinal Drugs and Biologics Market Dynamics

• 9.1 Retinal Drugs and Biologics Industry Trends
• 9.2 Retinal Drugs and Biologics Growth Drivers
• 9.3 Retinal Drugs and Biologics Market Challenges
• 9.4 Retinal Drugs and Biologics Market Restraints

10 Global Market Forecast

• 10.1 Retinal Drugs and Biologics Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Retinal Drugs and Biologics by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Retinal Drugs and Biologics by Type (2022-2027)
• 10.2 Retinal Drugs and Biologics Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Retinal Drugs and Biologics by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Retinal Drugs and Biologics by Application (2022-2027)
• 10.3 Retinal Drugs and Biologics Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Retinal Drugs and Biologics by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Retinal Drugs and Biologics by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List